@article {Wong1364, author = {L. Wong and H. T. See and H. S. Khoo-Tan and J. S. Low and W. T. Ng and J. J. Low}, title = {Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed m{\"u}llerian tumors of the uterus}, volume = {16}, number = {3}, pages = {1364--1369}, year = {2006}, doi = {10.1136/ijgc-00009577-200605000-00063}, publisher = {BMJ Specialist Journals}, abstract = {The role of adjuvant therapy for malignant mixed m{\"u}llerian tumors of the uterus has not been established. Our aim was to review our experience with sequential adjuvant therapy using cisplatin and ifosfamide chemotherapy and radiotherapy after surgical staging. A retrospective study of 43 patients from 1995 to 2004 was undertaken. Survival was calculated using the Kaplan{\textendash}Meier method and compared by the log-rank test. The Cox proportional hazard regression model was used to assess the effect of treatment on survival after adjustment for age and stage. Twenty-eight patients received adjuvant chemotherapy and 28 patients had adjuvant radiotherapy. Twenty-one patients underwent sequential adjuvant chemotherapy and radiotherapy. Tumor recurrence occurred in 14 patients at a median duration of 10 months. The overall 2- and 5-year survival was 64\% and 60\%, respectively. The 2- and 5-year survival for stage I and II diseases was both 95\%, while the 2-year survival for stage III and IV diseases was 25\%. Patients who underwent sequential adjuvant therapy had an improved survival compared with patients who did not follow the protocol (P = 0.024). Our results with sequential adjuvant therapy are encouraging and justify future randomized trials.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/16/3/1364}, eprint = {https://ijgc.bmj.com/content/16/3/1364.full.pdf}, journal = {International Journal of Gynecologic Cancer} }